查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
質粒 DNA 製造的全球市場：按業務規模、應用領域、治療領域和地區劃分：行業趨勢和預測，2023-2035 年
市場調查報告書
商品編碼
1328912

質粒 DNA 製造的全球市場：按業務規模、應用領域、治療領域和地區劃分：行業趨勢和預測，2023-2035 年

Plasmid DNA Manufacturing Market by Scale of Operation, Application Area, Therapeutic Area, and Geography: Industry Trends and Global Forecasts, 2023-2035
出版日期: | 出版商: Roots Analysis | 英文 255 Pages | 商品交期: 最快1-2個工作天內

價格

質粒 DNA 的開發和製造需要在時間、專業知識和資源方面進行大量投資。雖然一些大型製藥公司擁有內部生產設施，但許多其他藥物開發公司專注於 pDNA 製造業務，因為生產質粒 DNA 需要大量資本投資和復雜的基礎設施，並外包給服務提供商。因此，人們越來越重視旨在將 pDNA 製造業務外包給經驗豐富的合作夥伴的合作。外包提供了一個可行的解決方案，以克服與質粒穩定性相關的挑戰，並確保感興趣的 DNA 構建體的完整性和功能性。此外，擴大質粒 DNA 生產規模還存在一些挑戰，特別是在工藝開發、保持構建一致性和確保可重複性方面。這些技術和運營障礙使得製藥行業越來越依賴能夠提供與質粒製造相關的合同服務的質粒製造商。此外，由於對基於核酸的 COVID-19 疫苗的需求增加，COVID-19 大流行刺激了外包活動的激增。為了滿足這一緊迫的全球需求，許多疫苗開發商與合同服務提供商結成戰略聯盟，以有效滿足需求。

當前市場格局的特點是有 70 多家公司提供各種質粒 DNA 服務，包括質粒設計、質粒工程和質粒構建、工藝開發和優化以及質粒製造。有微型、小型、中型、大型和超大型公司，它們擁有必要的專業知識，可以在各種業務規模（包括臨床前、臨床和商業）提供 pDNA 製造服務。值得注意的是，大約 80% 的質粒製造商為商業規模應用提供 GMP 級質粒 DNA。

隨著 Touchlight 開發的 Doggybone DNA(TM) (dbDNA) 技術的出現，質粒 DNA 行業正在經歷一場突破性的革命。這種開創性的線性質粒技術是通過滾環擴增航空產生的，代表了該領域的突破。DbDNA(TM) 具有挑戰傳統質粒生產方法的獨特優勢，包括更高的穩定性、簡化的純化和經濟高效的可擴展性。dbDNA(TM) 在基因工程、基因治療和 mRNA 生產方面具有卓越的多功能性，使其成為一種極具前景的解決方案。有趣的是，2023 年2 月，Touchlight 獲得FDA 批准一項研究性新藥(IND) 申請，該申請利用狗骨DNA (dbDNA(TM)) 作為體外轉錄模板，用於細胞治療產品製造中的mRNA 生產。這些新的質粒 DNA 技術的採用將支持行業努力滿足細胞和 mRNA 療法對這種起始材料不斷增長的需求。在預測期內，新技術可能會推動質粒 DNA 製造市場的增長。

質粒製造行業的利益相關者已經建立了多個合作夥伴關係，以加強他們的服務組合併擴大其專有質粒 DNA 技術的範圍。值得注意的是，超過 55% 的合作夥伴關係是在 2021 年及以後成立的。值得注意的是，這些交易大部分集中在質粒產品的製造和供應上，其次是產品開發和技術獲取協議。2023 年 5 月，Aldevron 與 Evanor Biosciences 簽署了一項協議，利用該公司的新型大腸桿菌菌株改進發酵工藝。AcuraBio 與 Cytiva 於 2023 年 2 月達成的另一項類似協議採用 Cytiva 的一次性細菌質粒純化技術來擴展 cGMP pDNA 製造服務。

在基因療法廣泛採用和核酸疫苗需求不斷增長的推動下，質粒DNA製造市場預計在2023-2035年預測期內將以每年15%的速度增長。值得注意的是，在2023年的質粒DNA製造市場中，預計基因治療製造將佔據按應用領域劃分的大部分市場份額。

本報告考察了全球質粒 DNA 製造市場，並提供了市場概況、按業務規模、應用領域、治療領域、地區和進入市場的公司概況劃分的趨勢。

目錄

第一章 前言

第二章研究方法

第 3 章. 經濟和其他項目特定考慮因素

第 4 章執行摘要

第 5 章 簡介

第六章 市場總體情況

第 7 章主要見解

  • 章節概述
  • 質粒 DNA 服務提供商：重要見解

第 8 章 夥伴關係與合作

第9章 收購

  • 章節概述
  • 收購模式
  • 質粒DNA服務商：收購

第10章 能力分析

第十一章 企業競爭力分析

  • 章節概述
  • 假設和關鍵參數
  • 調查方法
  • 質粒DNA製造服務提供商：公司競爭力分析

第十二章公司簡介

  • 章節概述
  • AGC Biologics
  • Aldevron（Acquired by Danaher）
  • Biomay
  • Catalent Pharma Solutions
  • Charles River
  • Cytovance Biologics
  • Forge Biologics
  • GenScript ProBio（a Subsidiary of GenScript）
  • Patheon pharma services（Acquired by Thermo Fisher Scientific）
  • VGXI
  • 53Biologics
  • Boehringer Ingelheim
  • Centre for Breakthrough Medicine（CBM）
  • JAFRAL Biosolutions
  • PackGene
  • Acural Bio
  • Hanmi BioPlant
  • BioCina
  • NorthXBiologics
  • Xpress Biologics
  • Eurogentec
  • ESCO Aster
  • Southern RNA
  • Richter-Helm
  • Aurigene Pharmaceutical Services
  • Wuxi AppTech

第十三章需求分析

14 市場影響分析：驅動因素、限制因素、機遇和挑戰

  • 章節概述
  • 市場驅動力
  • 市場限制
  • 市場機會
  • 市場挑戰
  • 結論

第十五章全球質粒 DNA 製造市場

第 16 章 質粒 DNA 製造市場（按業務規模）

17 質粒 DNA 製造市場（按應用）

18 質粒 DNA 製造市場，按治療領域

第十九章 質粒 DNA 製造市場（按地區）

第20章結論

第21章管理見解

第22章附錄1：表格數據

第二十三章 附錄2：公司和組織名單

Product Code: RA100448

INTRODUCTION

The global plasmid DNA manufacturing market is estimated to be worth over USD XX billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of ~15% during the forecast period.

The plasmid DNA manufacturing market is a dynamic and rapidly growing sector that plays a pivotal role in biotechnology and genetic research. Plasmid DNA is a circular, double-stranded DNA molecule that replicates independently of chromosomal DNA. With its ability to be genetically engineered, plasmid DNA serves as a crucial component in the development of advanced therapy medicinal products (ATMPs), such as cell and gene therapy, and nucleic acid vaccines. Having said that, it is important to highlight that the current demand for plasmid DNA is experiencing an exponential growth due to the expanding landscape of cell and gene therapies. This surge in demand got further amplified in the global COVID-19 pandemic, as plasmid-based delivery became an indispensable approach in the development of RNA/DNA vaccines and therapeutics. During this time, several big pharma players, including Moderna and Pfizer-BioNTech utilized plasmid-based platforms for their mRNA vaccines, which significantly contributed towards increased demand for plasmid DNA.

However, the process of plasmid production is fraught with various challenges, including low yield, plasmid instability, and regulatory concerns, which necessitate specialized facilities and adherence to good manufacturing practices (GMP). As a result, an increasing number of researchers and drug developers are relying on contract service providers with specialized expertise and advanced technologies for their GMP plasmid manufacturing requirements. These service providers offer comprehensive services, including process development and optimization, plasmid construction, plasmid design, and plasmid engineering. In addition, there are specialty service providers that help to streamline the pDNA manufacturing process, optimize resource utilization, and ensure the delivery of high quality of plasmid DNA to fulfil the rigorous requirements of regulatory authorities and research standards. With growing demand for ATMPs and the increasing trend of outsourcing pDNA manufacturing operations, the pDNA manufacturing market is expected to witness substantial growth during the forecast period.

SCOPE OF THE REPORT

The "Plasmid DNA Manufacturing Market: Distribution by Scale of Operation (Commercial, Clinical and Preclinical), Application Area (Cell Therapy Manufacturing, Gene Therapy Manufacturing, DNA / RNA Vaccine Development, Viral Vector Manufacturing, and Other Application Areas), Therapeutic Area (Metabolic Disorders, Neurological Disorders, Oncological Disorders, Rare Disorders, and Other Disorders), and Geography (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2023-2035" report features an extensive study of the current market landscape, market size and future opportunities within the plasmid DNA manufacturing market during the forecast period. The market report highlights the efforts of various stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the plasmid DNA manufacturing market are briefly discussed below.

Enhanced Reliability on pDNA Manufacturing Service Providers

The development and manufacturing of plasmid DNA requires significant investment in terms of time, expertise and resources. While a few large pharmaceutical companies have established in-house manufacturing facilities, the need for substantial capital investment and complex infrastructure to produce plasmid DNA has led many other drug developers to outsource pDNA manufacturing operations to specialized service providers. Consequently, there has been an increased emphasis on collaboration, aimed at outsourcing pDNA manufacturing operations to experienced partners. Outsourcing offers a viable solution to overcome challenges associated with plasmid stability, ensuring the integrity and functionality of the desired DNA constructs. Further, there are several challenges in scaling up plasmid DNA production particularly in process development, maintaining construct consistency, and ensuring reproducibility. These technical and operational obstacles have prompted pharmaceutical industry to increasingly rely on plasmid manufacturer with capability to provide contract services related to plasmid manufacturing. Additionally, the COVID-19 pandemic has fueled a surge in outsourcing activities, because of the rising demand for nucleic acid-based COVID-19 vaccines. In response to this urgent global need, numerous vaccine developers have established strategic collaborations with contract service providers to effectively meet the demand.

Plasmid Manufacturer Market Landscape

The current market landscape features the presence of over 70 companies offering a range of plasmid DNA services, including plasmid design, plasmid engineering and plasmid construction, process development and optimization, and plasmid manufacturing. Overall, the market seems to be well-fragmented, featuring the presence of very small, small, mid-sized, large, and very large companies having the required expertise to offer pDNA manufacturing services across different scales of operations, such as preclinical, clinical, and commercial. It is worth mentioning that around 80% of the plasmid manufacturer offer GMP grade plasmid DNA for commercial scale applications; notable examples (which have also been captured in this market report) include AGC Biologics, Aldevron, Biomay, Catalent Pharma Solutions, Charles River, Cytovance Biologics, Forge Biologics, GenScript ProBio, Thermo Fisher Scientific, and VGXI.

Technology Trends: Doggybone DNATM is Likely to Revolutionize Gene Therapy

The plasmid DNA industry is on the verge of groundbreaking revolution, driven by the emergence of Doggybone DNA™ (dbDNA) technology developed by Touchlight. This pioneering linear plasmid technology, produced abiotically through rolling circle amplification, represents a seismic shift in this field. DbDNA™ offers unparalleled advantages, including enhanced stability, simplified purification, and cost-effective scalability, challenging conventional plasmid production methods. With its remarkable versatility in genetic engineering, gene therapy, and mRNA production, dbDNA™ stands as a highly promising solution. It is interesting to note that in February 2023, Touchlight received FDA clearance for the Investigational New Drug (IND) application utilizing doggybone DNA (dbDNA™) as an in vitro transcription template for mRNA production in the manufacturing of a cell-based therapy product. Adoption of such novel plasmid DNA technologies will support the efforts of the industry to meet the growing demand for this starting material for cell therapy and mRNA based therapy. Novel technologies will propel the plasmid DNA manufacturing market growth during the forecast period.

Leading Companies Engaged in Plasmid DNA Manufacturing Market

Examples of key plasmid manufacturer (which have also been profiled in this report) offering pDNA manufacturing services include (in alphabetical order) AGC Biologics, Aldevron, Biomay, Charles River, Cytovance Biologics, Forge Biologics, GenScript ProBio, Thermo Fisher Scientific, and VGXI. It is interesting to note that in January 2023, Charles River expanded its portfolio by launching eXpDNA™ plasmid manufacturing platform, in order to offer efficient and accelerated GMP plasmid manufacturing and supply services to ATMP developers. Such portfolio additions are expected to drive plasmid DNA manufacturing market growth during the forecast period.

Expansion of Facilities for Building GMP Plasmid Manufacturing Capabilities

The players in this market are continuously expanding their facilities in order to accommodate the growing demand for plasmid DNA. They are vigorously advancing their capabilities to serve as a fully integrated one-stop-shop by offering a range of plasmid services, including process development and optimization, plasmid design, plasmid engineering and plasmid construct, and GMP plasmid manufacturing. In January 2023, Catalent Pharma Solutions, a US-based CDMO, established a new commercial scale plasmid development and manufacturing facility to expand its end-to-end capabilities for the production of GMP grade plasmid DNA. Increase in the demand for plasmid DNA to support the production of cell and gene therapies is one of the reasons for the facility / capability expansion by the contract organizations.

Market Trends: Partnership and Collaboration on the Rise for Plasmid DNA Manufacturing

Stakeholders in the plasmid manufacturing industry have forged several partnerships in order to enhance their service portfolios and augment the reach of their proprietary plasmid DNA technology. It is worth highlighting that over 55% of these partnerships have been inked since 2021. Notably, majority of such deals are focused on manufacturing and supply of plasmid products, followed by product development and technology utilization agreements. In May 2023, Aldevron signed an agreement with Evanoa Bioscience to improve its fermentation process by using latter's novel strains of Escherichia Coli. In another similar deal inked between AcuraBio and Cytiva in February 2023, the former company adopted Cytiva's single-use bacterial plasmid purification technology to expand its cGMP pDNA manufacturing service.

Plasmid DNA Manufacturing Market Size: Gene Therapy Market Segment to Hold the Largest Market Share

Driven by the increasing adoption of gene therapies and rising demand for nucleic acid vaccines, the plasmid DNA manufacturing market is anticipated to grow at an annualized rate (CAGR) of ~15% during the forecast period 2023-2035. It is worth highlighting that, in terms of application area, gene therapy manufacturing is expected to capture the majority market share in the plasmid DNA manufacturing market in 2023.

Recent Developments

Several recent developments have taken place in the field of plasmid manufacturing. Some of these recent initiatives have been mentioned below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we have outlined in our analyses.

  • In June 2023, INADcure Foundation announced a manufacturing alliance with Charles River Laboratories, under which the latter will be responsible for manufacturing high quality pDNA for phase I/II clinical trials of a gene therapy against Infantile Neuroaxonal Dystrophy.
  • In February 2023, BioNTech, a leader in mRNA-based vaccine and therapy developer, announced the completion of its in-house clinical and commercial scale pDNA manufacturing facility at Marburg, Germany.

The market report presents an in-depth analysis, highlighting the capabilities of various companies engaged in this industry, across different geographies. Amongst other elements, the market research report features:

  • A preface providing an introduction to the full report, Plasmid DNA Manufacturing Market, 2023-2035.
  • An outline of the systematic research methodology adopted to conduct the study on plasmid DNA manufacturing market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
  • An overview of economic factors that impact the overall plasmid DNA manufacturing market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
  • An executive summary of the key insights captured during our research, offering a high-level view on the current state of the plasmid DNA manufacturing market and its likely evolution in the short to mid and long term.
  • A general overview of plasmid DNA, highlighting details on different types of plasmids based on their function. It also features the various applications of plasmid DNA in the pharmaceutical industry. Further, it provides information on the challenges associated with pDNA manufacturing, as well as the growing need for outsourcing the production of such products.
  • An overview of the current market landscape of plasmid DNA service providers based on relevant parameters, such as year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe, Asia, and rest of the world), type of company (CDMOs, CMOs, CROs/CMOs, CROs, suppliers and others), type of venture (private companies, acquired by public companies, public companies, acquired by private companies), type of service(s) offered (plasmid design, and plasmid construction, process development and optimization, and plasmid manufacturing), location of manufacturing facility (North America, Europe, Asia and rest of the world), key offerings (proprietary technology / platforms and plasmid DNA products), grade of plasmid DNA (research grade plasmid DNA, and GMP grade plasmid DNA), scale of operation (preclinical, clinical, and commercial) and application area(s) (cell and gene therapy manufacturing, DNA / RNA vaccine development, viral vector manufacturing, and other application areas).
  • An insightful analysis, highlighting the contemporary market trends in the plasmid DNA manufacturing market through different representations, based on relevant parameters, such as company size and location of headquarters; company size and type of venture; key offerings and location of headquarters; scale of operation and company size; grade of plasmid DNA and application area(s); scale of operation, application area(s) and location of manufacturing facility.
  • A detailed analysis of the partnerships inked between various stakeholders engaged in this market, since 2015, covering manufacturing and supply agreements, product development and manufacturing agreements, technology utilization agreements, service alliances, and product development agreements.
  • A detailed analysis of the acquisitions reported in plasmid manufacturing market, during the period 2015-2023. It is worth mentioning that the data captured during our research was analyzed based on multiple parameters, such as year of acquisition, type of acquisition, geographical location, company size and ownership of the companies involved, key value drivers, and acquisition deal multiples (based on revenues).
  • An estimate of the overall installed pDNA manufacturing capacity of industry players based on the information available in the public domain, and insights generated via both secondary and primary research. It also highlights the distribution of global capacity by company size (very small, small, mid-sized, large and very large), grade of plasmid DNA (research grade plasmid DNA, and GMP grade plasmid DNA), scale of operation (pre-commercial and commercial), and location of manufacturing facility (North America, Europe, Asia and rest of the world).
  • A detailed competitiveness analysis of pDNA manufacturing service providers based on supplier power (based on the experience), their respective capabilities (types of services offered, grade of plasmid DNA, scale of operation, application areas, total capacity, number of acquisitions) and partnership activity (in terms of number of partnerships and type of agreement).
  • Elaborate profiles of prominent players (shortlisted based on our proprietary company competitiveness) engaged in offering plasmid manufacturing services. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), details related to its financial performance (if available), recent developments and an informed future outlook.
  • An in-depth analysis to estimate the current and future demand for plasmid DNA, based on several relevant parameters, such as scale of operation (commercial, clinical and preclinical), application area (cell therapy manufacturing, gene therapy manufacturing, DNA / RNA vaccine development, and viral vector manufacturing), and geography (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World) for the period 2023-2035. Kindly note that input parameters considered for this analysis include target patient population, dosing frequency and dose strength.
  • An in-depth analysis of the factors that can impact the growth of plasmid DNA manufacturing market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.

The key objective of this market report is to provide a detailed market forecast analysis in order to estimate the existing market size and future opportunity for plasmid manufacturer over the next decade. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2023-2035. The report also features the likely distribution of the current and forecasted opportunity within the plasmid DNA manufacturing market across various segments, such as scale of operation (commercial, clinical, and preclinical), application area (cell therapy manufacturing, gene therapy manufacturing, DNA / RNA vaccine development, and viral vector manufacturing, and other application areas), therapeutic area (metabolic disorders, neurological disorders, oncological disorders, rare disorders, and other disorders), and geography (North America, Europe, Asia, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Frenk Smrekar (Chief Executive Officer and Co-Founder, JAFRAL Biosolutions)
  • Jeff Briganti (Senior Director of Global Strategic Marketing, Aldevron)
  • Francisco Manuel Reyes Sosa (Business Development Manager, 53Biologics)
  • Blaine Rathmann (Client Engagement Manager, Center for Breakthrough Medicines)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming 12 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED

Question 1: What are the steps in plasmid DNA manufacturing?

Answer: The steps involved in plasmid DNA manufacturing include plasmid design and plasmid construction, host cell transformation, culture expansion, plasmid isolation and purification, and quality control testing.

Question 2: What is GMP plasmid manufacturing?

Answer: GMP plasmid manufacturing involves compliance with comprehensive quality control and assurance standards, including facility design, equipment qualification, raw material selection, process controls, documentation, quality control testing, and personnel training, in order to ensure the production of high-quality plasmid DNA.

Question 3: Who manufactures plasmid DNA?

Answer: Plasmid DNA is manufactured by various organizations, including biotechnology companies, contract manufacturing organizations (CMOs), contract development and manufacturing organizations (CDMOs), academic institutions, and research laboratories with the necessary capabilities and expertise in molecular biology and bioprocessing.

Question 4: Who are the key players in the plasmid DNA manufacturing market?

Answer: Examples of key players engaged in the plasmid manufacturing market (which have also been captured in this report) include AGC Biologics, Aldevron, Biomay, Catalent Pharma Solutions, Charles River, Cytovance Biologics, Forge Biologics, GenScript ProBio, Thermo Fisher Scientific, and VGXI.

Question 5: What is the size of the plasmid manufacturing market?

Answer: The global plasmid DNA manufacturing market is expected to be worth around USD XX billion by 2035.

Question 6: What are the leading market segments in the plasmid DNA manufacturing market?

Answer: Currently, in terms of scale of operation, commercial scale manufacturing of plasmid DNA captures the largest market share. Further, in terms of therapeutic area, metabolic disorders and oncology are expected to capture a prominent share of the current and future market.

Question 7: Which region has the highest market share in plasmid DNA manufacturing market?

Answer: Currently, North America and Europe collectively hold around 70% of the market share. However, in the long run, the pDNA manufacturing market in Asia is expected to grow at a relatively faster pace.

Question 8: What is the plasmid DNA manufacturing market growth?

Answer: The global plasmid manufacturing market revenue is anticipated to grow at a compound annual growth rate (CAGR) of ~15%, during the forecast period, 2023-2035.

Question 9: What are the factors driving the plasmid DNA manufacturing market?

Answer: Advancements in genetic engineering, coupled with the increasing demand for genetically modified therapies and nucleic acid vaccines will lead to a significant growth in the plasmid DNA manufacturing market, over the forecast period.

Question 10: What are the upcoming trends in the plasmid DNA manufacturing market?

Answer: The plasmid DNA manufacturing market is witnessing a shift towards automation, with the implementation of robotic systems and automated technologies across various manufacturing stages. This has led to enhanced efficiency, scalability, and productivity; for instance, the use of robotic systems for high-throughput screening of transformed cells enabled rapid identification and selection of desired plasmid constructs with improved efficiency and accuracy.

CHAPTER OUTLINES

  • Chapter 1 is a preface providing an introduction to the full report, Plasmid DNA Manufacturing Market, 2023-2035.
  • Chapter 2 is an outline of the systematic research methodology adopted to conduct the study on plasmid DNA manufacturing market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of findings.
  • Chapter 3 provides an overview of economic factors that impact the overall plasmid DNA manufacturing market, which include historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
  • Chapter 4 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state of the plasmid DNA manufacturing market and its likely evolution in the short to mid and long term.
  • Chapter 5 provides a general overview of the plasmid DNA, highlighting the different types of plasmid DNA based on their function. It also features the various applications of plasmid DNA in the pharmaceutical industry. Further, provides information on the challenges associated with plasmid DNA manufacturing, as well as the growing need for outsourcing the production of such products.
  • Chapter 6 is an overview of the current market landscape of plasmid DNA service providers based on relevant parameters, such as year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe, Asia, and rest of the world), type of company (CDMOs, CMOs, CROs/CMOs, CROs, suppliers and others), type of venture (private companies, acquired by public companies, public companies, acquired by private companies), type of service(s) offered (plasmid design, engineering and construct, process development and optimization, and plasmid manufacturing), location of manufacturing facility (North America, Europe, Asia and rest of the world), key offerings (proprietary technology / platform and plasmid DNA products), grade of plasmid DNA (research grade plasmid DNA, and GMP grade plasmid DNA), scale of operation (preclinical, clinical, and commercial), and application area(s) (cell and gene therapy manufacturing, DNA / RNA vaccine development, viral vector manufacturing, and other application areas).
  • Chapter 7 presents an insightful analysis, highlighting the contemporary market trends in the plasmid DNA manufacturing market through different representations, based on relevant parameters, such as company size and location of headquarters; company size and type of venture; key offerings and location of headquarters; scale of operation and company size; grade of plasmid DNA and application area(s); scale of operation, application area(s) and location of manufacturing facility.
  • Chapter 8 includes detailed analysis of the partnerships inked between stakeholders engaged in this market, since 2015, covering manufacturing and supply agreements, product development and manufacturing agreements, technology utilization agreements, service alliances, and product development agreements.
  • Chapter 9 presents insights from a detailed analysis of the acquisitions reported in plasmid DNA manufacturing market, during the period 2015-2023. It is worth mentioning that the data captured during our research was analyzed based on multiple parameters, such as year of acquisition, type of acquisition, geographical location, company size and ownership of the companies involved, key value drivers, and acquisition deal multiples (based on revenues).
  • Chapter 10 provides an estimate of the overall installed plasmid DNA manufacturing capacity of industry players based on the information available in the public domain, and insights generated via both secondary and primary research. The analysis also highlights the distribution of the global capacity by company size (very small, small, mid-sized, large and very large), grade of plasmid DNA (research grade plasmid DNA, and GMP grade plasmid DNA), scale of operation (pre-commercial and commercial), and location of manufacturing facility (North America, Europe, Asia and rest of the world).
  • Chapter 11 provides a detailed competitiveness analysis of plasmid DNA manufacturing service providers based on supplier power (based on the experience), their respective capabilities (types of services offered, grade of plasmid DNA, scale of operation, application areas, total capacity, number of acquisitions) and partnership activity (in terms of number of partnerships and type of agreement).
  • Chapter 12 includes detailed profiles of various prominent players (shortlisted based on our proprietary company competitiveness) engaged in offering plasmid DNA manufacturing services. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), details related to its financial performance (if available), recent developments and an informed future outlook.
  • Chapter 13 includes an elaborate analysis in order to estimate the current and future demand for plasmid DNA, based on several relevant parameters, scale of operation (commercial, clinical and preclinical), application area (cell therapy manufacturing, gene therapy manufacturing, DNA / RNA vaccine development, and viral vector manufacturing), and geography (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World) for the period 2023-2035. Kindly note that input parameters considered for this analysis include target patient population, dosing frequency and dose strength.
  • Chapter 14 present an in-depth analysis of the factors that can impact the growth of plasmid DNA manufacturing market. In addition, it includes identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
  • Chapter 15 a detailed market forecast analysis in order to estimate the existing market size and future opportunity for plasmid DNA manufacturers over the next decade. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2023-2035. The report also features the likely distribution of the current and forecasted opportunity within the plasmid DNA manufacturing market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
  • Chapter 16 provides detailed projections of the current and future plasmid DNA manufacturing market across different scales of operation, such as commercial, clinical and preclinical.
  • Chapter 17 provides detailed projections of the current and future plasmid DNA manufacturing market across various application areas, such as cell therapy manufacturing, gene therapy manufacturing, DNA / RNA vaccine development, viral vector manufacturing, other application areas.
  • Chapter 18 provides detailed projections of the current and future plasmid DNA manufacturing market across therapeutic areas, such as metabolic disorders, neurological disorders, oncological disorders, rare disorders, and other disorders.
  • Chapter 19 provides detailed projections of the current and future plasmid DNA manufacturing market across various geographies, such as North America, Europe, Asia, Latin America, Middle East and North Africa and rest of the world.
  • Chapter 20 summarizes the entire report, highlighting various facts related to contemporary market trends and the likely evolution of the plasmid DNA manufacturing market, based on the research and analysis described in the previous chapters.
  • Chapter 21 is a collection of interview transcripts of discussions held with various key stakeholders in this market. It provides a brief overview of the companies and details of interviews held with Frenk Smrekar (Chief Executive Officer and Co-Founder, JAFRAL Biosolutions), Jeff Briganti (Senior Director of Global Strategic Marketing, Aldevron), Francisco Manuel Reyes Sosa (Business Development Manager, 53Biologics), and Blaine Rathmann (Client Engagement Manager, Center for Breakthrough Medicines).
  • Chapter 22 is an appendix, which contains tabulated data and numbers for all the figures included in this report.
  • Chapter 23 is an appendix, which contains a list of companies and organizations mentioned in this report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Project Objectives
  • 1.3. Scope of the Report
  • 1.4. Inclusions and Exclusions
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Overview of Plasmids
    • 5.2.1. Structure of a Plasmid DNA
  • 5.3. Types of Plasmids (By Function)
    • 5.3.1. Fertility Plasmids
    • 5.3.2. Resistance Plasmids
    • 5.3.3. Virulence Plasmids
    • 5.3.4. Degradative Plasmids
    • 5.3.5. Col Plasmids
  • 5.4. Plasmid DNA Manufacturing
    • 5.4.1. Steps Involved in Plasmid DNA Manufacturing
  • 5.5. Applications of Plasmid DNA in Pharmaceutical Industry
    • 5.5.1. Cell and Gene Therapy Manufacturing
    • 5.5.2. Viral Vector Manufacturing
    • 5.5.3. Vaccine Development
    • 5.5.4. Other Research Applications
  • 5.6. Challenges Associated with Plasmid DNA Manufacturing
  • 5.7 Need for Outsourcing Plasmid DNA Manufacturing
  • 5.8 Future Perspectives

6. OVERALL MARKET LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Plasmid DNA Service Providers: Overall Market Landscape
  • 6.3. Analysis by Year of Establishment

6. 4. Analysis by Company Size

  • 6.5. Analysis by Location of Headquarters
  • 6.6. Analysis by Type of Company
  • 6.7. Analysis by Type of Venture
  • 6.8. Analysis by Type of Service(s) Offered
    • 6.8.1. Analysis by Location of Manufacturing Facility

6.9. Analysis by Key Offerings

6.10. Analysis by Grade of Plasmid DNA

6.11. Analysis by Scale of Operation

6.12. Analysis by Application Area(s)

7. KEY INSIGHTS

  • 7.1. Chapter Overview
  • 7.2. Plasmid DNA Service Providers: Key Insights

7.2.1 Analysis by Company Size and Location of Headquarters

7.2.2. Analysis by Company Size and Type of Venture

7.2.3. Analysis by Key Offerings and Location of Headquarters

7.2.4. Analysis by Scale of Operation and Company Size

7.2.5. Analysis by Grade of Plasmid DNA and Application Area(s)

7.2.6. Analysis by Scale of Operation, Application Area(s) and Location of Manufacturing Facility

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Plasmid DNA Services: Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Year and Type of Partnership
    • 8.3.4. Analysis by Type of Partner
    • 8.3.5. Analysis by Type of Partnership and Type of Partner
    • 8.3.6. Analysis by Grade of Plasmid DNA
    • 8.3.7. Analysis by Scale of Operation
    • 8.3.8 Analysis by Geography
      • 8.3.8.1. Local and International Agreements
      • 8.3.8.2. Intercontinental and Intracontinental Agreements
    • 8.3.9. Most Active Players: Analysis by Number of Partnerships

9. ACQUISITIONS

  • 9.1. Chapter Overview
  • 9.2. Acquisitions Models
  • 9.3. Plasmid DNA Services Providers: Acquisitions
    • 9.3.1. Analysis by Year of Acquisition
    • 9.3.2. Analysis by Type of Acquisition
    • 9.3.3. Analysis by Geography
      • 9.3.3.1. Local and International Acquisitions
      • 9.3.3.2. Intercontinental and Intracontinental Acquisitions

9.3.4. Ownership Change Matrix

9.3.5. Analysis by Company Size

9.3.6. Analysis by Key Value Drivers

9.3.7. Valuation Analysis: Acquisition Deal Multiples

9.3.8. Most Active Players: Analysis by Number of Acquisitions

10. CAPACITY ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Key Assumptions and Methodology
  • 10.3. Plasmid DNA Manufacturing: Global Installed Capacity
    • 10.3.1. Analysis by Company Size
    • 10.3.2. Analysis by Scale of Operation
    • 10.3.3. Analysis by Location of Manufacturing Facility
  • 10.4. Concluding Remarks

11. COMPANY COMPETITIVENSS ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Assumptions and Key Parameters
  • 11.3. Methodology
  • 11.4. Plasmid DNA Manufacturing Service Providers: Company Competitiveness Analysis
    • 11.4.1. Benchmarking of Service Strength
    • 11.3.2. Benchmarking of Partnership Activity
    • 11.3.3. Very Small Companies Offering Plasmid DNA Manufacturing
    • 11.3.4. Small Companies Offering Plasmid DNA Manufacturing
    • 11.3.5. Mid-Sized Companies Offering Plasmid DNA Manufacturing
    • 11.3.6. Large Companies Offering Plasmid DNA Manufacturing
    • 11.3.7. Very Large Companies Offering Plasmid DNA Manufacturing

12. COMPANY PROFILES

  • 12.1. Chapter Overview
  • 12.2. AGC Biologics
    • 12.2.1. Company Overview
    • 12.2.2. Service Portfolio
    • 12.2.3. Recent Developments and Future Outlook
  • 12.3. Aldevron (Acquired by Danaher)
    • 12.3.1. Company Overview
    • 12.3.2. Service Portfolio
    • 12.3.3. Financial Information
    • 12.3.4. Recent Developments and Future Outlook
  • 12.4. Biomay
    • 12.4.1. Company Overview
    • 12.4.2. Service Portfolio
    • 12.4.3. Recent Developments and Future Outlook
  • 12.5. Catalent Pharma Solutions
    • 12.5.1. Company Overview
    • 12.5.2. Service Portfolio
    • 12.5.3. Financial Information
    • 12.5.4. Recent Developments and Future Outlook
  • 12.6. Charles River
    • 12.6.1. Company Overview
    • 12.6.2. Service Portfolio
    • 12.6.3. Financial Information
    • 12.6.4. Recent Developments and Future Outlook
  • 12.7. Cytovance Biologics
    • 12.7.1. Company Overview
    • 12.7.2. Service Portfolio
    • 12.7.3. Recent Developments and Future Outlook
  • 12.8. Forge Biologics
    • 12.8.1. Company Overview
    • 12.8.2. Service Portfolio
    • 12.8.3. Recent Developments and Future Outlook
  • 12.9. GenScript ProBio (a Subsidiary of GenScript)
    • 12.9.1. Company Overview
    • 12.9.2. Service Portfolio
    • 12.9.3. Financial Information
    • 12.9.4. Recent Developments and Future Outlook
  • 12.10. Patheon pharma services (Acquired by Thermo Fisher Scientific)
    • 12.10.1. Company Overview
    • 12.10.2. Service Portfolio
    • 12.10.3. Financial Information
    • 12.10.4. Recent Developments and Future Outlook
  • 12.11. VGXI
    • 12.11.1. Company Overview
    • 12.11.2. Service Portfolio
    • 12.11.3. Recent Developments and Future Outlook
  • 12.12. 53Biologics
    • 12.12.1. Company Overview
    • 12.11.2. Service Portfolio
  • 12.13. Boehringer Ingelheim
    • 12.13.1. Company Overview
    • 12.13.2. Service Portfolio
  • 12.14. Centre for Breakthrough Medicine (CBM)
    • 12.14.1. Company Overview
    • 12.14.2. Service Portfolio
  • 12.15. JAFRAL Biosolutions
    • 12.15.1. Company Overview
    • 12.15.2. Service Portfolio
  • 12.16. PackGene
    • 12.16.1. Company Overview
    • 12.16.2. Service Portfolio
  • 12.17. Acural Bio
    • 12.17.1. Company Overview
    • 12.17.2. Service Portfolio
  • 12.18. Hanmi BioPlant
    • 12.18.1. Company Overview
    • 12.18.2. Service Portfolio
  • 12.19. BioCina
    • 12.19.1. Company Overview
    • 12.19.2. Service Portfolio
  • 12.20. NorthXBiologics
    • 12.21.1. Company Overview
    • 12.22.2. Service Portfolio
  • 12.21. Xpress Biologics
    • 12.21.1. Company Overview
    • 12.21.2. Service Portfolio
  • 12.22. Eurogentec
    • 12.22.1. Company Overview
    • 12.22.2. Service Portfolio
  • 12.23. ESCO Aster
    • 12.23.1. Company Overview
    • 12.23.2. Service Portfolio
  • 12.24. Southern RNA
    • 12.24.1. Company Overview
    • 12.24.2. Service Portfolio
  • 12.25. Richter-Helm
    • 12.25.1. Company Overview
    • 12.25.2. Service Portfolio
  • 12.26. Aurigene Pharmaceutical Services
    • 12.26.1. Company Overview
    • 12.26.2. Service Portfolio
  • 12.27. Wuxi AppTech
    • 12.27.1. Company Overview
    • 12.27.2. Service Portfolio

13. DEMAND ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Key Assumptions and Methodology
  • 13.3. Global Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 13.3.1. Analysis by Scale of Operation
      • 13.3.1.1. Commercial Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 13.3.1.2. Clinical Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 13.3.1.3. Preclinical Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 13.3.2. Analysis by Application Area
      • 13.3.2.1. Plasmid DNA Demand for Cell Therapy Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 13.3.2.2. Plasmid DNA Demand for Gene Therapy Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 13.3.2.3. Plasmid DNA Demand for DNA / RNA Vaccine Development, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 13.3.2.4. Plasmid DNA Demand for Viral Vector Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 13.3.2.5. Plasmid DNA Demand for Other Application Areas, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 13.3.3. Analysis by Geography
      • 13.3.3.1. Demand for Plasmid DNA in North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 13.3.3.2. Demand for Plasmid DNA in Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 13.3.3.3. Demand for Plasmid DNA in Asia, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 13.3.3.4. Demand for Plasmid DNA in Latin America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 13.3.3.5. Demand for Plasmid DNA in Middle East and North Africa, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 13.3.3.6. Demand for Plasmid DNA in Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)

14. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 14.1. Chapter Overview
  • 14.2. Market Drivers
  • 14.3. Market Restraints
  • 14.4. Market Opportunities
  • 14.5. Market Challenges
  • 14.6. Conclusion

15. GLOBAL PLASMID DNA MANUFACTURING MARKET

  • 15.1. Chapter Overview
  • 15.2. Assumptions and Methodology
  • 15.3. Global Plasmid DNA Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 15.3.1. Scenario Analysis
  • 15.4. Key Market Segmentations
  • 15.5. Dynamic Dashboard

16. PLASMID DNA MANUFACTURING MARKET, BY SCALE OF OPERATION

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Methodology
  • 16.3. Commercial Products: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 16.4. Clinical Products: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 16.5. Preclinical Products: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 16.6. Data Triangulation
    • 16.6.1. Insights from Primary Research
    • 16.6.2. Insights from Secondary Research
    • 16.6.3. Insights from In-house Repository

17. PLASMID DNA MANUFACTURING MARKET, BY APPLICATION AREA

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Cell Therapy Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 17.4. DNA / RNA Vaccine Development: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 17.5. Viral Vector Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 17.6. Other Application Areas: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 17.8. Data Triangulation
    • 17.8.1. Insights based on Primary Research
    • 17.8.2. Insights based on Secondary Research
    • 17.8.3. Insights from In-house Repository

18. PLASMID DNA MANUFACTURING MARKET, BY THERAAPEUTIC AREA

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Metabolic Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.4. Neurological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.5. Oncological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.6. Rare Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.7. Other Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.8. Data Triangulation
    • 18.8.1. Insights based on Primary Research
    • 18.7.2. Insights based on Secondary Research
    • 18.7.3. Insights from In-house Repository

19. PLASMID DNA MANUFACTURING MARKET, BY GEOGRAPHY

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.4. Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.5. Asia: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.6. Latin America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.7. Middle East and North Africa: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.8. Rest of the World: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.9. Data Triangulation
    • 19.9.1. Insights based on Primary Research
    • 19.9.2. Insights based on Secondary Research
    • 19.9.3. Insights from In-house Repository

20. CONCLUSION

21. EXECUTIVE INSIGHTS

  • 21.1. Chapter Overview
  • 21.2. JAFRAL Biosolutions
    • 21.2.1. Company Snapshot
    • 21.2.2. Interview Transcript: Frenk Smrekar, Chief Executive Officer and Co-Founder
  • 21.3. Aldevron (Acquired by Danaher)
    • 21.3.1. Company Snapshot
    • 21.3.2. Interview Transcript: Jeff Briganti, Senior Director of Global Strategic Marketing
  • 21.4. 53Biologics
    • 21.4.1. Company Snapshot
    • 21.4.2. Interview Transcript: Francisco Manuel Reyes Sosa, Business Development Manager
  • 21.5. Center for Breakthrough Medicines (CBM)
    • 21.5.1. Company Snapshot
    • 21.5.2. Interview Transcript: Blaine Rathmann, Client Engagement Manager

22. APPENDIX 1: TABULATED DATA

23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF TABLES

  • Table 6.1 List of Plasmid DNA Service Providers
  • Table 6.2 Plasmid DNA Service Providers: Information on Type of Service(s) Offered
  • Table 6.3 Plasmid DNA Manufacturing Service Providers: Information on Location of Manufacturing Facility
  • Table 6.4 Plasmid DNA Service Providers: Information on Key Offerings
  • Table 6.5 Plasmid DNA Service Providers: Information on Grade of Plasmid DNA
  • Table 6.6 Plasmid DNA Service Providers: Information on Scale of Operation
  • Table 6.7 Plasmid DNA Service Providers: Information on Application Area(s)
  • Table 8.1 Plasmid DNA Services: List of Partnerships and Collaborations, 2015-2023
  • Table 8.2 Partnerships and Collaborations: Information on Type of Agreement (Country- wise and Continent-wise), 2015-2023
  • Table 9.1 Plasmid DNA Service Providers: List of Acquisitions, 2015-2023
  • Table 10.1 Plasmid DNA Manufacturers: Information on Production Capacity
  • Table 12.1 AGC Biologics: Company Snapshot
  • Table 12.2 AGC Biologics: Service Portfolio
  • Table 12.3 AGC Biologics: Recent Developments and Future Outlook
  • Table 12.4 Aldevron (Acquired by Danaher): Company Snapshot
  • Table 12.5 Aldevron (Acquired by Danaher): Service Portfolio
  • Table 12.6 Aldevron (Acquired by Danaher): Recent Development and Future Outlook
  • Table 12.7 Biomay: Company Snapshot
  • Table 12.7 Biomay: Service Portfolio
  • Table 12.8 Biomay: Recent Developments and Future Outlook
  • Table 12.9 Catalent Pharma Solutions: Company Snapshot
  • Table 12.10 Catalent Pharma Solutions: Service Portfolio
  • Table 12.11 Catalent Pharma Solutions: Recent Developments and Future Outlook
  • Table 12.12 Charles River: Company Snapshot
  • Table 12.13 Charles River: Service Portfolio
  • Table 12.14 Charles River: Recent Developments and Future Outlook
  • Table 12.15 Cytovance Biologics: Company Snapshot
  • Table 12.16 Cytovance Biologics: Service Portfolio
  • Table 12.17 Cytovance Biologics: Recent Developments and Future Outlook
  • Table 12.18 Forge Biologics: Company Snapshot
  • Table 12.19 Forge Biologics: Service Portfolio
  • Table 12.20 Forge Biologics: Recent Developments and Future Outlook
  • Table 12.21 GenScript ProBio (a Subsidiary of GenScript): Company Snapshot
  • Table 12.22 GenScript ProBio (a Subsidiary of GenScript): Service Portfolio
  • Table 12.23 GenScript ProBio (a Subsidiary of GenScript): Recent Development and Future Outlook
  • Table 12.24 Patheon pharma services (acquired by Thermo Fisher Scientific): Company Snapshot
  • Table 12.25 Patheon pharma services (acquired by Thermo Fisher Scientific): Service Portfolio
  • Table 12.26 Patheon pharma services (acquired by Thermo Fisher Scientific): Recent Developments and Future Outlook
  • Table 12.27 VGXI: Company Snapshot
  • Table 12.28 VGXI: Service Portfolio
  • Table 12.29 VGXI: Recent Developments and Future Outlook
  • Table 12.30 53Biologics: Service Portfolio
  • Table 12.31 Boehringer Ingelheim: Service
  • Table 12.32 Centre for Breakthrough
  • Table 12.33 JAFRAL Biosolutions: Service
  • Table 12.34 PackGene: Service Portfolio
  • Table 12.35 Acural Bio: Service Portfolio
  • Table 12.36 Hanmi BioPlant: Service
  • Table 12.37 BioCina: Service Portfolio
  • Table 12.38 NorthXBiologics: Service
  • Table 12.39 Xpress Biologics: Service
  • Table 12.40 Eurogentec: Service Portfolio
  • Table 12.41 ESCO Aster: Service Portfolio
  • Table 12.42 Southern RNA: Service Portfolio
  • Table 12.43 Richter-Helm: Service Portfolio
  • Table 12.44 Aurigene Pharmaceutical: Service Portfolio
  • Table 12.45 Wuxi AppTech: Service Portfolio
  • Table 22.1 Plasmid DNA Service Providers: Distribution by Year of Establishment
  • Table 22.2 Plasmid DNA Service Providers: Distribution by Company Size
  • Table 22.3 Plasmid DNA Service Providers: Distribution by Location of Headquarters
  • Table 22.4 Plasmid DNA Service Providers: Distribution by Type of Company
  • Table 22.5 Plasmid DNA Service Providers: Distribution by Type of Venture
  • Table 22.6 Plasmid DNA Service Providers: Distribution by Type of Service(s) Offered
  • Table 22.7 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
  • Table 22.8 Plasmid DNA Service Providers: Distribution by Key Offerings
  • Table 22.9 Plasmid DNA Service Providers: Distribution by Grade of Plasmid DNA
  • Table 22.10 Plasmid DNA Service Providers: Distribution by Scale of Operation
  • Table 22.11 Plasmid DNA Service Providers: Distribution by Application Area(s)
  • Table 22.12 Key Insights: Distribution by Company Size and Location of Headquarters
  • Table 22.13 Key Insights: Distribution by Company Size and Type of Venture
  • Table 22.14 Key Insights: Distribution by Key Offerings and Location of Headquarters
  • Table 22.15 Key Insights: Distribution by Scale of Operation and Company Size
  • Table 22.16 Key Insights: Distribution by Grade of Plasmid DNA and Application Area(s)
  • Table 22.18 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015-2023
  • Table 22.19 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 22.20 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2023
  • Table 22.21 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 22.22 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Table 22.23 Partnerships and Collaborations: Distribution by Grade of Plasmid DNA
  • Table 22.24 Partnerships and Collaborations: Distribution by Scale of Operation
  • Table 22.25 Partnerships and Collaborations: Local and International Agreements
  • Table 22.26 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 22.27 Most Active Players: Distribution by Number of Partnerships
  • Table 22.28 Acquisitions: Cumulative Year-Wise Trend, 2015-2023
  • Table 22.29 Acquisitions: Distribution by Type of Acquisition
  • Table 22.30 Acquisitions: Local and International Deals
  • Table 22.31 Acquisitions: Intercontinental and Intracontinental Deals
  • Table 22.32 Acquisitions: Ownership Change Matrix
  • Table 22.33 Acquisitions: Distribution by Company Size
  • Table 22.34 Acquisitions: Distribution by Key Value Drivers
  • Table 22.35 Acquisitions: Valuation by Acquisition Deal Multiples
  • Table 22.36 Most Active Players: Distribution by Number of Acquisitions
  • Table 22.37 Minimum, Average and Maximum Installed Plasmid DNA Manufacturing Capacity (Sample Dataset) (in Liters): Distribution by Company Size
  • Table 22.38 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Company Size
  • Table 22.39 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Scale of Operation
  • Table 22.40 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Location of Manufacturing Facility
  • Table 22.41 Company Competitiveness Analysis: Benchmarking of Service Strength
  • Table 22.42 Company Competitiveness Analysis: Benchmarking of Partnership Activity
  • Table 22.43 Danaher: Annual Revenues, 2017-2022 (USD Billion)
  • Table 22.44 Catalent Pharma Solutions: Annual Revenues, 2017-2022 (USD Billion)
  • Table 22.45 Charles River: Annual Revenues, 2017-2022 (USD Billion)
  • Table 22.46 GenScript: Annual Revenues, 2017-2022 (USD Billion)
  • Table 22.47 Thermo Fisher Scientific: Annual Revenues, 2017-2022 (USD Billion)
  • Table 22.48 Global Demand for Plasmid DNA, Historical Trends (2018- 2022) (In Kgs)
  • Table 22.49 Global Demand for Plasmid DNA, Forecasted Estimates (2023-2035) (In Kgs)
  • Table 22.50 Demand for Plasmid DNA: Distribution by Scale of Operation, Historical Trends (2018-2022) (In Kgs)
  • Table 22.51 Demand for Plasmid DNA: Distribution by Scale of Operation, Forecasted Estimates (2023-2035) (In Kgs)
  • Table 22.52 Demand for Plasmid DNA: Distribution by Application Area, Historical Trends (2018- 2022) (In Kgs)
  • Table 22.53 Demand for Plasmid DNA: Distribution by Application Area, Forecasted Estimates (2023-2035) (In Kgs)
  • Table 22.54 Demand for Plasmid DNA: Distribution by Geography, Historical Trends (2018-2022) (In Kgs)
  • Table 22.55 Demand for Plasmid DNA: Distribution by Geography, Forecasted Estimates (2023- 2035) (In Kgs)
  • Table 22.56 Global Plasmid DNA Manufacturing Market, Historical Trends (2018-2022) (USD Billion)
  • Table 22.57 Global Plasmid DNA Manufacturing Market, Forecasted Estimates (2023- 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 22.58 Plasmid DNA Manufacturing Market: Distribution by Scale of Operation, Historical Trends (2018-2022) (USD Billion)
  • Table 22.59 Plasmid DNA Manufacturing Market: Distribution by Scale of Operation, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 22.60 Plasmid DNA Manufacturing Market: Distribution by Application Area, Historical Trends (2018-2022) (USD Billion)
  • Table 22.61 Plasmid DNA Manufacturing Market: Distribution by Application Area, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 22.62 Plasmid DNA Manufacturing Market: Distribution by Therapeutic Area, Historical Trends (2018-2022) (USD Billion)
  • Table 22.63 Plasmid DNA Manufacturing Market: Distribution by Therapeutic Area, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 22.64 Plasmid DNA Manufacturing Market: Distribution by Geography, Historical Trend (2018-2022) (USD Billion)
  • Table 22.65 Plasmid DNA Manufacturing Market: Distribution by Geography, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Billion)

LIST OF FIGURES

  • Figure 4.1 Executive Summary: Overall Market Landscape
  • Figure 4.2 Executive Summary: Partnerships and Collaborations
  • Figure 4.3 Executive Summary: Acquisitions
  • Figure 4.4 Executive Summary: Capacity Analysis
  • Figure 4.5 Executive Summary: Demand Analysis
  • Figure 4.6 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 5.1 Steps Involved in Plasmid DNA Manufacturing
  • Figure 5.2 Applications of Plasmid DNA in Pharmaceutical Industry
  • Figure 5.3 Challenges Associated with Plasmid DNA Manufacturing
  • Figure 6.1 Plasmid DNA Service Providers: Distribution by Year of Establishment
  • Figure 6.2 Plasmid DNA Service Providers: Distribution by Company Size
  • Figure 6.3 Plasmid DNA Service Providers: Distribution by Location of Headquarters (Region-wise)
  • Figure 6.4 Plasmid DNA Service Providers: Distribution by Location of Headquarters (Country-wise)
  • Figure 6.5 Plasmid DNA Service Providers: Distribution by Type of Company
  • Figure 6.6 Plasmid DNA Service Providers: Distribution by Type of Venture
  • Figure 6.7 Plasmid DNA Service Providers: Distribution by Type of Service(s) Offered
  • Figure 6.8 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
  • Figure 6.9 Plasmid DNA Service Providers: Distribution by Key Offerings
  • Figure 6.10 Plasmid DNA Service Providers: Distribution by Grade of Plasmid DNA
  • Figure 6.11 Plasmid DNA Service Providers: Distribution by Scale of Operation
  • Figure 6.12 Plasmid DNA Service Providers: Distribution by Application Area(s)
  • Figure 7.1 Key Insights: Distribution by Company Size and Location of Headquarters
  • Figure 7.2 Key Insights: Distribution by Company Size and Type of Venture
  • Figure 7.3 Key Insights: Distribution by Key Offerings and Location of Headquarters
  • Figure 7.4 Key Insights: Distribution by Scale of Operation and Company Size
  • Figure 7.5 Key Insights: Distribution by Grade of Plasmid DNA and Application Area(s)
  • Figure 7.6 Key Insights: Distribution by Scale of Operation, Application Area(s) and Location of Manufacturing Facility
  • Figure 8.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015-2023
  • Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2023
  • Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Figure 8.6 Partnerships and Collaborations: Distribution by Grade of Plasmid DNA
  • Figure 8.7 Partnerships and Collaborations: Distribution by Scale of Operation
  • Figure 8.8 Partnerships and Collaborations: Local and International Agreements
  • Figure 8.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 8.10 Most Active Players: Distribution by Number of Partnerships
  • Figure 9.1 Acquisitions: Cumulative Year-Wise Trend, 2015-2023
  • Figure 9.2 Acquisitions: Distribution by Type of Acquisition
  • Figure 9.3 Acquisitions: Local and International Deals
  • Figure 9.4 Acquisitions: Intercontinental and Intracontinental Deals
  • Figure 9.5 Acquisitions: Ownership Change Matrix
  • Figure 9.6 Acquisitions: Distribution by Company Size
  • Figure 9.7 Acquisitions: Distribution by Key Value Drivers
  • Figure 9.8 Acquisitions: Valuation by Acquisition Deal Multiples
  • Figure 9.9 Most Active Players: Distribution by Number of Acquisitions
  • Figure 10.1 Minimum, Average and Maximum Installed Plasmid DNA Manufacturing Capacity (Sample Dataset) (in Liters): Distribution by Company Size
  • Figure 10.2 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Company Size
  • Figure 10.3 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Scale of Operation
  • Figure 10.4 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Location of Manufacturing Facility
  • Figure 11.1 Company Competitiveness Analysis: Benchmarking of Service Strength
  • Figure 11.2 Company Competitiveness Analysis: Benchmarking of Partnership Activity
  • Figure 11.3 Company Competitiveness Analysis: Very Small Companies Offering Plasmid DNA Manufacturing
  • Figure 11.4 Company Competitiveness Analysis: Small Companies Offering Plasmid DNA Manufacturing
  • Figure 11.5 Company Competitiveness Analysis: Mid-Sized Companies Offering Plasmid DNA Manufacturing
  • Figure 11.6 Company Competitiveness Analysis: Large Companies Offering Plasmid DNA Manufacturing
  • Figure 11.7 Company Competitiveness Analysis: Very Large Companies Offering Plasmid DNA Manufacturing
  • Figure 12.1 Danaher: Annual Revenues, 2017-2022 (USD Billion)
  • Figure 12.2 Catalent Pharma Solutions: Annual Revenues, 2017-2022 (USD Billion)
  • Figure 12.3 Charles River: Annual Revenues, 2017-2022 (USD Billion)
  • Figure 12.4 GenScript: Annual Revenues, 2017-2022 (USD Billion)
  • Figure 12.5 Thermo Fisher Scientific: Annual Revenues, 2017-2022 (USD Billion)
  • Figure 13.1 Global Demand for Plasmid DNA, Historical Trends (2018- 2022) and Forecasted Estimates (2023-2035) (In Kgs)
  • Figure 13.2 Demand for Plasmid DNA: Distribution by Scale of Operation, 2018, 2023 and 2035
  • Figure 13.3 Commercial Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (In Kgs)
  • Figure 13.4 Clinical Demand for Plasmid DNA, Historical Trends (2018- 2022) and Forecasted Estimates (2023-2035) (In Kgs)
  • Figure 13.5 Preclinical Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (In Kgs)
  • Figure 13.6 Demand for Plasmid DNA: Distribution by Application Area, 2018, 2023 and 2035
  • Figure 13.7 Plasmid DNA Demand for Cell Therapy Manufacturing, Historical Trends (2018- 2022) and Forecasted Estimates (2023-2035) (In Kgs)
  • Figure 13.8 Plasmid DNA Demand for Gene Therapy Manufacturing, Historical Trends (2018- 2022) and Forecasted Estimates (2023-2035) (In Kgs)
  • Figure 13.9 Plasmid DNA Demand for DNA / RNA Vaccine Development, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (In Kgs)
  • Figure 13.10 Plasmid DNA Demand for Viral Vector Manufacturing, Historical Trends (2018- 2022) and Forecasted Estimates (2023-2035) (In Kgs)
  • Figure 13.11 Plasmid DNA Demand for Other Application Areas, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • Figure 13.12 Demand for Plasmid DNA: Distribution by Geography, 2018, 2023 and 2035
  • Figure 13.13 Demand for Plasmid DNA in North America, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (In Kgs)
  • Figure 13.14 Demand for Plasmid DNA in Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (In Kgs)
  • Figure 13.15 Demand for Plasmid DNA in Asia, Historical Trends (2018- 2022) and Forecasted Estimates (2023-2035) (In Kgs)
  • Figure 13.16 Demand for Plasmid DNA in Latin America, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (In Kgs)
  • Figure 13.17 Demand for Plasmid DNA in Middle East and North Africa, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (In Kgs)
  • Figure 13.18 Demand for Plasmid DNA in Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (In Kgs)
  • Figure 15.1 Global Plasmid DNA Manufacturing Market, Historical Trends (2018-2022)
  • Figure 15.2 Global Plasmid DNA Manufacturing Market, Forecasted Estimates (2023- 2035), Base Scenario (USD Million)
  • Figure 15.3 Global Plasmid DNA Manufacturing Market, Forecasted Estimates (2023- 2035), Conservative Scenario (USD Billion)
  • Figure 15.4 Global Plasmid DNA Manufacturing Market, Forecasted Estimates (2023- 2035), Optimistic Scenario (USD Billion)
  • Figure 16.1 Plasmid DNA Manufacturing Market: Distribution by Scale of Operation, 2018, 2023 and 2035
  • Figure 16.2 Plasmid DNA Manufacturing Market for Commercial Products, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
  • Figure 16.3 Plasmid DNA Manufacturing Market for Clinical Products, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
  • Figure 16.4 Plasmid DNA Manufacturing Market for Preclinical Products, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
  • Figure 17.1 Plasmid DNA Manufacturing Market: Distribution by Application Area, 2018, 2023 and 2035
  • Figure 17.2 Plasmid DNA Manufacturing Market for Cell Therapy Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
  • Figure 17.3 Plasmid DNA Manufacturing Market for Gene Therapy Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
  • Figure 17.4 Plasmid DNA Manufacturing Market for DNA / RNA Vaccine Development, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
  • Figure 17.5 Plasmid DNA Manufacturing Market for Viral Vector Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
  • Figure 17.6 Plasmid DNA Manufacturing Market for Other Application Areas, Historical Trends (2018- 2022) and Forecasted Estimates (2023-2035) (USD Billion)
  • Figure 14.12 Plasmid DNA Manufacturing Market: Distribution by Therapeutic Area, 2018, 2023 and 2035
  • Figure 18.1 Plasmid DNA Manufacturing Market for Metabolic Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
  • Figure 18.2 Plasmid DNA Manufacturing Market for Neurological Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
  • Figure 18.3 Plasmid DNA Manufacturing Market for Oncological Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
  • Figure 18.4 Plasmid DNA Manufacturing Market for Rare Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
  • Figure 18.5 Plasmid DNA Manufacturing Market for Other Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
  • Figure 19.1 Plasmid DNA Manufacturing Market: Distribution by Geography, 2018, 2023 and 2035
  • Figure 19.2 Plasmid DNA Manufacturing Market in North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
  • Figure 19.3 Plasmid DNA Manufacturing Market in Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
  • Figure 19.4 Plasmid DNA Manufacturing Market in Asia, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
  • Figure 19.5 Plasmid DNA Manufacturing Market in Latin America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
  • Figure 19.6 Plasmid DNA Manufacturing Market in Middle East and North Africa, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
  • Figure 19.7 Plasmid DNA Manufacturing Market in Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
  • Figure 20.1 Concluding Remarks: Overall Market Landscape
  • Figure 20.2 Concluding Remarks: Partnerships and Collaborations
  • Figure 20.3 Concluding Remarks: Acquisitions
  • Figure 20.4 Concluding Remarks: Company Competitiveness Analysis
  • Figure 20.5 Concluding Remarks: Capacity Analysis
  • Figure 20.6 Concluding Remarks: Demand Analysis
  • Figure 20.7 Concluding Remarks: Market Forecast and Opportunity Analysis (I/II)
  • Figure 20.8 Concluding Remarks: Market Forecast and Opportunity Analysis (II/II)
  • Figure 20.9 Concluding Remarks: Key Growth Drivers and Restraints